Abstract
Multiparametric MRI (mp-MRI) has become a standard imaging modality in the diagnostic workup for prostate cancer. It significantly improves staging accuracy due to the excellent sensitivity and specificity in identifying extraprostatic extension and seminal vesicle invasion.
There is a strong dose-response relationship between radiation and dominant intraprostatic lesion (DIL). Given the dose-painting capability of brachytherapy and stereotactic body radiotherapy (SBRT), MRI-guided dose escalation to DIL can significantly improve therapeutic ratio in prostate radiotherapy.
During planning of radiation treatment with prostate MRI, T2-weighted MRI images are fused with CT simulation images to improve target and normal organ delineation. The SpaceOAR hydrogel spacer that displaces rectum away from prostate has been approved by FDA and routinely used in prostate radiotherapy. T2W/CT fusion technique is also used in post-seed implant dosimetry.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Muralidhar V, Dinh KT, Mahal BA, et al. Differential post-prostatectomy cancer-specific survival of occult t3 vs. Clinical t3 prostate cancer: Implications for managing patients upstaged on prostate magnetic resonance imaging. Urol Oncol. 2015;33(7):330.e19–25. https://doi.org/10.1016/j.urolonc.2015.03.010.
Wang L, Hricak H, Kattan MW, et al. Prediction of organ-confined prostate cancer: incremental value of MR imaging and MR spectroscopic imaging to staging nomograms. Radiology. 2006;238:597–603.
D’Amico AV, Schnall M, Whittington R, et al. Endorectal coil magnetic resonance imaging identifies locally advanced prostate cancer in select patients with clinically localized disease. Urology. 1998;51:449–54.
Hegde JV, Chen MH, Mulkern RV, et al. Preoperative 3-tesla multiparametric endorectal magnetic resonance imaging findings and the odds of upgrading and upstaging at radical prostatectomy in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2013;85(2):e101–7. https://doi.org/10.1016/j.ijrobp.2012.08.032.
Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an eortc study): a phase iii randomised trial. Lancet. 2002;360(9327):103–6.
Stock RG, Cahlon O, Cesaretti JA, et al. Combined modality treatment in the management of high-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2004;59:1352–9.
Kuban DA, Tucker SL, Dong L, et al. Long-term results of the m. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys. 2008;70:67–74.
Cellini N, Morganti AG, Mattiucci GC, et al. Analysis of intraprostatic failures in patients treated with hormonal therapy and radiotherapy: implications for conformal therapy planning. Int J Radiat Oncol Biol Phys. 2002;53:595–9.
Gomez-Iturriaga A, Casquero F, Urresola A, et al. Dose escalation to dominant intraprostatic lesions with MRI-transrectal ultrasound fusion high-dose-rate prostate brachytherapy. Prospective phase ii trial. Radiother Oncol. 2016;119(1):91–6. https://doi.org/10.1016/j.radonc.2016.02.004.
Miralbell R, Molla M, Rouzaud M, et al. Hypofractionated boost to the dominant tumor region with intensity modulated stereotactic radiotherapy for prostate cancer: a sequential dose escalation pilot study. Int J Radiat Oncol Biol Phys. 2010;78(1):50–7. https://doi.org/10.1016/j.ijrobp.2009.07.1689.
Sundahl N, De Meerleer G, Villeirs G, et al. Combining high dose external beam radiotherapy with a simultaneous integrated boost to the dominant intraprostatic lesion: analysis of genito-urinary and rectal toxicity. Radiother Oncol. 2016;119(3):398–404. https://doi.org/10.1016/j.radonc.2016.04.031.
Georg D, Hopfgartner J, Gora J, et al. Dosimetric considerations to determine the optimal technique for localized prostate cancer among external photon, proton, or carbon-ion therapy and high-dose-rate or low-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys. 2014;88(3):715–22. https://doi.org/10.1016/j.ijrobp.2013.11.241.
Nguyen PL, D'Amico AV, Lee AK, et al. Patient selection, cancer control, and complications after salvage local therapy for postradiation prostate-specific antigen failure: a systematic review of the literature. Cancer. 2007;110(7):1417–28.
Yamada Y, Kollmeier MA, Pei X, et al. A phase ii study of salvage high-dose-rate brachytherapy for the treatment of locally recurrent prostate cancer after definitive external beam radiotherapy. Brachytherapy. 2014;13(2):111–6. https://doi.org/10.1016/j.brachy.2013.11.005.
Dinis Fernandes C, van Houdt PJ, Heijmink S, et al. Quantitative 3t multiparametric MRI of benign and malignant prostatic tissue in patients with and without local recurrent prostate cancer after external-beam radiation therapy. J Magn Reson Imaging. 2019;50(1):269–78. https://doi.org/10.1002/jmri.26581.
Pucar D, Hricak H, Shukla-Dave A, et al. Clinically significant prostate cancer local recurrence after radiation therapy occurs at the site of primary tumor: magnetic resonance imaging and step-section pathology evidence. Int J Radiat Oncol Biol Phys. 2007;69:62–9.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Guo, G. (2020). Prostate MRI from Radiation Oncology Perspective. In: Tirkes, T. (eds) Prostate MRI Essentials. Springer, Cham. https://doi.org/10.1007/978-3-030-45935-2_11
Download citation
DOI: https://doi.org/10.1007/978-3-030-45935-2_11
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-45934-5
Online ISBN: 978-3-030-45935-2
eBook Packages: MedicineMedicine (R0)